| 1.32 0.02 (1.54%) | 05-08 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.8 | 1-year : | 1.99 |
| Resists | First : | 1.54 | Second : | 1.71 |
| Pivot price | 1.38 |
|||
| Supports | First : | 1.26 | Second : | 1.05 |
| MAs | MA(5) : | 1.31 |
MA(20) : | 1.39 |
| MA(100) : | 1.12 |
MA(250) : | 1.15 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 9.8 |
D(3) : | 9.4 |
| RSI | RSI(14): 48.7 |
|||
| 52-week | High : | 1.71 | Low : | 0.87 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CRDL ] has closed above bottom band by 31.2%. Bollinger Bands are 64.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 29 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.34 - 1.35 | 1.35 - 1.35 |
| Low: | 1.26 - 1.27 | 1.27 - 1.28 |
| Close: | 1.31 - 1.32 | 1.32 - 1.33 |
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Thu, 07 May 2026
Heart pain study lands in cardiology journal as trial tops 75% enrollment - Stock Titan
Thu, 07 May 2026
Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association - ChartMill
Tue, 28 Apr 2026
Cardiol Therapeutics (CRDL) Expands MAVERIC Trial with New Clini - GuruFocus
Wed, 15 Apr 2026
Cardiol Therapeutics CEO: Phase III MAVERIC Nears Full Enrollment as CardiolRx Shows Myocarditis Promise - Yahoo Finance
Tue, 14 Apr 2026
Cardiol Therapeutics (CRDL) CEO to discuss MAVERIC, ARCHER and CRD-38 in X interview - Stock Titan
Tue, 14 Apr 2026
Cardiol CEO goes live on X to discuss Phase III heart drug trial - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 112 (M) |
| Shares Float | 96 (M) |
| Held by Insiders | 2.4 (%) |
| Held by Institutions | 21.9 (%) |
| Shares Short | 1,980 (K) |
| Shares Short P.Month | 2,100 (K) |
| EPS | -0.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.12 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -77.4 % |
| Return on Equity (ttm) | -158.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.31 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -24 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -4.56 |
| PEG Ratio | 0 |
| Price to Book value | 10.15 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.19 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|